CK Life Sciences Int'l (Holdings) Inc - Company Profile
Powered by 
All the sales intelligence you need on CK Life Sciences Int'l (Holdings) Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how CK Life Sciences Int'l (Holdings) Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with CK Life Sciences Int'l (Holdings) Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
CK Life Sciences Int'l (Holdings) Inc (CK Life) is an investment holding company that focuses on healthcare research and development, agriculture-related businesses, and nutraceuticals. The company offers a range of products, including plant protection solutions, specialty nutrition products, eco-fertilizer products, soil conditioners, and nutritional supplements. CK Life develops clinical-stage cancer vaccines, oncology treatments, and pain management therapeutics. It also offers advanced, AI-driven drug discovery and molecular design platforms through strategic research. It has operations in Australia, Canada, New Zealand, China, Hong Kong, the US, and the Virgin Islands, among others. The company's products serve various industries, such as professional turf management, home gardening, pest management, and healthcare. CK Life is headquartered in Hong Kong.
Headquarters
Hong Kong
Address
2 Dai Fu Street, Tai Po Industrial Estate, Tai Po, Hong Kong City
Website
www.ck-lifesciences.com
Telephone
852 212 61212
No of Employees
1,920
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
775 (HKG)
Revenue (2024)
$694.0M
-2%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-47.6%
(2024 vs 2023)
Market Cap*
$661.6M
Net Profit Margin (2024)
XYZ
-50.7%
(2024 vs 2023)
* As of and is in US$
CK Life Sciences Int'l (Holdings) Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Human Health and Nutraceuticals: | Seviprotimut-L |
| Vitamins | Halneuron |
| Minerals | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Divestiture | In April, the company sold Polynoma LLC to TransCode Therapeutics Inc, an RNA oncology company. |
| 2026 | Corporate Changes/Expansions | In March, the company established Sequencio Therapeutics Company Limited to advance therapeutic cancer vaccines development. |
| 2022 | Contracts/Agreements | In November, the company announced a strategic collaboration with XtalPi to jointly develop AI-empowered tumour vaccine R&D platform. |
Competitor Comparison
| Key Parameters | CK Life Sciences Int'l (Holdings) Inc | Shanghai Pharmaceuticals Holding Co Ltd | Nanjing Pharmaceutical Group Co Ltd | China Medical System Holdings Ltd | China Shineway Pharmaceutical Group Ltd |
|---|---|---|---|---|---|
| Headquarters | Hong Kong | China | China | Hong Kong | China |
| City | Hong Kong City | Shanghai | Nanjing | Hong Kong City | Shijiazhuang |
| State/Province | - | Shanghai | Jiangsu | - | Hebei |
| No. of Employees | 1,920 | 49,608 | 4,697 | 6,415 | 2,822 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Li Tzar Kuoi Victor | Chairman | Executive Board | 2002 | 61 |
| Yu Ying Choi, Alan Abel | Chief Executive Officer; Deputy Chairman | Executive Board | 2026 | 70 |
| Ip Tak Chuen Edmond | Chief Investment Officer; Director; Senior Vice President | Executive Board | 2021 | 73 |
| Toh Kean Meng Melvin | Chief Scientific Officer; Director; Vice President | Executive Board | 2021 | 59 |
| Wong Wun Lam Peter | Chief Financial Officer | Senior Management | - | 60 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer